Overview:
Kedrion is an international company that collects and splits human plasma to produce and distribute plasma-derived therapeutic products for use in the treatment of diseases, diseases and serious conditions such as haemophilia and immune deficiency. It is the 5th world player and the 1st in Italy in the plasma derivatives sector. It has 6 production plants, located in Italy, USA and Hungary, with a commercial presence in about 100 countries. It has a turnover of 659.3 million Euros in 2016, and has about 2,300 employees, about 1,000 in Italy. Kedrion has always invested in R&D for the development of plasma-derived orphan drugs for the treatment of particularly rare pathologies, and since 2011 has opened in Siena, in collaboration with Toscana Life Sciences, the IKOD facility, authorised by AIFA to produce experimental biological blood-derived medicines.
